These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21753885)

  • 1. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.
    Masumori N
    Ther Clin Risk Manag; 2011; 7():227-38. PubMed ID: 21753885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia.
    Griwan MS; Karthikeyan YR; Kumar M; Singh BJ; Singh SK
    Urol Ann; 2014 Jul; 6(3):181-6. PubMed ID: 25125888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of naftopidil in the management of benign prostatic hyperplasia.
    Hara N; Mizusawa T; Obara K; Takahashi K
    Ther Adv Urol; 2013 Apr; 5(2):111-9. PubMed ID: 23554846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
    Shirakawa T; Haraguchi T; Shigemura K; Morishita S; Minayoshi K; Miyazaki J; Yamada Y; Miyake H; Tanaka K; Fujisawa M
    Int J Urol; 2013 Sep; 20(9):903-10. PubMed ID: 23252453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
    Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of α
    Nagata Y; Kawahara T; Goto T; Inoue S; Teramoto Y; Jiang G; Fujimoto N; Miyamoto H
    Am J Cancer Res; 2020; 10(12):4386-4398. PubMed ID: 33415006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
    Castiglione F; Benigni F; Briganti A; Salonia A; Villa L; Nini A; Di Trapani E; Capitanio U; Hedlund P; Montorsi F
    Curr Med Res Opin; 2014 Apr; 30(4):719-32. PubMed ID: 24188134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
    Fonseca J; Martins da Silva C
    Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
    J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia.
    Shigemura K; Yamamichi F; Matsumoto M; Tanaka K; Yamashita M; Arakawa S; Fujisawa M
    Low Urin Tract Symptoms; 2012 Sep; 4(3):136-9. PubMed ID: 26676620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Efficacy of an α1 Adrenoceptor Antagonist, Naftopidil, against Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.
    Ishizuka O; Nishizawa O; Takeda M; Nomura T; Kagawa S
    Low Urin Tract Symptoms; 2011 Sep; 3(2):79-85. PubMed ID: 26676391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
    BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Momose H; Hosokawa Y; Kishino T; Ono T; Oyama N
    Drugs Today (Barc); 2007 Feb; 43 Suppl A():1-10. PubMed ID: 17401467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
    Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
    Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    Kadekawa K; Sugaya K; Mukoyama H; Sakumoto M; Shimabukuro H; Shimabukuro S; Matayoshi Y; Onaga T; Ashitomi K; Nishijima S
    Low Urin Tract Symptoms; 2016 May; 8(2):100-5. PubMed ID: 27111621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.